Clinical outcomes of the use of subcutaneous daratumumab for donor-derived cell-free DNA guided treatment of antibody mediated rejection in asian kidney transplant recipients at the Singapore General Hospital (TTS 2026) - Sep 17, 2026 - Pres time: Sep 23, 2026; 08:30 AM - 08:37 AM; Location: Room C3.3; 403; "Introduction: Long-term kidney transplant (KTX) survival following treatment of antibody mediated rejection (ABMR) with standard of care therapies like plasmaphresis, intravenous immunoglobulin and rituximab remains poor...In recent years, anti-CD38+ therapies have gained interest especially following a randomized controlled trial showing that Felzartamab resolved ABMR in 80% of cases... Our preliminary experience with DARA treatment for ABMR is positive since all experienced a decline in dd-cfDNA but is limited by the lack of follow-up biopsies in most patients."
cfDNA • Clinical • Clinical data • IO biomarker • Antibody-mediated Rejection • Cardiovascular • Immunology • Inflammation • Transplantation
|
|
Terence Kee1,2; Ian Tatt Liew1; Carolyn Tien1; Quan Yao Ho1; Sobhana Thangaraju1,2
|